Literature DB >> 24333306

Plasma-derived medicinal products self-sufficiency from national plasma: to what extent?

Vincenzo De Angelis1, Antonio Breda2.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24333306      PMCID： PMC3853994          DOI： 10.2450/2013.019s

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  15 in total

Review 1.  The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.

Authors:  E Tabor
Journal:  Transfusion       Date:  1999 Nov-Dec       Impact factor: 3.157

2.  Best practices in regulation of blood and blood products.

Authors:  Jay S Epstein
Journal:  Biologicals       Date:  2011-11-27       Impact factor: 1.856

3.  Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.

Authors:  Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

4.  Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers).

Authors:  P M Mannucci; A Gringeri; F Peyvandi; E Santagostino
Journal:  Haemophilia       Date:  2007-12       Impact factor: 4.287

5.  Sustainability of a public system for plasma collection, contract fractionation and plasma-derived medicinal product manufacturing.

Authors:  Giuliano Grazzini; Anna Ceccarelli; Deanna Calteri; Liviana Catalano; Gabriele Calizzani; Americo Cicchetti
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 6.  Improving availability and affordability of plasma-derived medicines.

Authors:  Abdol Majid Cheraghali; Hassan Abolghasemi
Journal:  Biologicals       Date:  2010-01       Impact factor: 1.856

Review 7.  Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.

Authors:  A Iorio; S Halimeh; S Holzhauer; N Goldenberg; E Marchesini; M Marcucci; G Young; C Bidlingmaier; L R Brandao; C E Ettingshausen; A Gringeri; G Kenet; R Knöfler; W Kreuz; K Kurnik; D Manner; E Santagostino; P M Mannucci; U Nowak-Göttl
Journal:  J Thromb Haemost       Date:  2010-03-17       Impact factor: 5.824

8.  The Dublin Consensus Statement 2011 on vital issues relating to the collection and provision of blood components and plasma-derived medicinal products.

Authors:  B O'Mahony; A Turner
Journal:  Vox Sang       Date:  2011-08-01       Impact factor: 2.144

Review 9.  How we choose factor VIII to treat hemophilia.

Authors:  Pier Mannuccio Mannucci; Maria Elisa Mancuso; Elena Santagostino
Journal:  Blood       Date:  2012-03-12       Impact factor: 22.113

Review 10.  Self-sufficiency, free trade and safety.

Authors:  Jukka Rautonen
Journal:  Biologicals       Date:  2010-01-13       Impact factor: 1.856
View more
  4 in total

1.  Plasma-derived medicinal products: demand and clinical use.

Authors:  Giuliano Grazzini; Pier Mannuccio Mannucci; Fabrizio Oleari
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

2.  Trends in Plasma Toll Fractionation for Self Sufficiency of Plasma-Derived Medicinal Products in Italy.

Authors:  Vincenzo De Angelis; Antonio Breda
Journal:  Transfus Med Hemother       Date:  2019-02-05       Impact factor: 3.747

Review 3.  Implementation of Plasma Fractionation in Biological Medicines Production.

Authors:  Kamran Mousavi Hosseini; Mehran Ghasemzadeh
Journal:  Iran J Biotechnol       Date:  2016-12       Impact factor: 1.671

4.  Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.

Authors:  Kai Uwe Radomski; Georg Lattner; Torben Schmidt; Jürgen Römisch
Journal:  BioDrugs       Date:  2017-04       Impact factor: 5.807
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.